IMARA Inc.

NasdaqGS:IMRA Rapport sur les actions

Capitalisation boursière : US$165.8m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

IMARA Gestion

Gestion contrôle des critères 4/4

Informations clés

Rahul Ballal

Directeur général

US$2.0m

Rémunération totale

Pourcentage du salaire du PDG26.54%
Durée du mandat du directeur général4.7yrs
Propriété du PDG0.08%
Durée moyenne d'occupation des postes de direction3.8yrs
Durée moyenne du mandat des membres du conseil d'administration4.1yrs

Mises à jour récentes de la gestion

Recent updates

Seeking Alpha • Oct 13

Cancer drug developer Enliven Therapeutics and Imara to merge in all-stock deal

Pharmaceutical firms Enliven Therapeutics and Imara (NASDAQ:IMRA) have agreed to merge in an all-stock transaction. The combined company will focus on advancing Enliven's pipeline of precision oncology product candidates, IMRA said in a statement on Thursday. Enliven has two cancer drug candidates. The merged entity will be renamed Enliven Therapeutics and is expected to trade on the Nasdaq Global Select Market under the ticker symbol ELVN. To support the merger, Enliven also intends to raise about $165M in a concurrent private financing co-led by new investors Fairmount and Venrock Healthcare Capital Partners. The combined company is expected to have a cash balance of about $300M at close. IMRA stock earlier closed +4.5% at $2.58.
Seeking Alpha • Sep 29

Imara: Potential Liquidation

Summary Imara has announced strategic alternatives and has announced the sale its key asset. It now trades 37% below its Pro Forma net cash levels and a liquidation would be ideal. The main risk here is management pursuing a reverse-merger. Imara (IMRA) is a failed $60m MCAP biotech company trading at a 37% discount to its Pro Forma net cash levels. In April, the company reduced its workforce by around 83% (to a total of 6 employees), discontinued its treatment development pipeline (relating to both IMR-687 and IMR-261), and commenced a strategic review. A couple of positive developments have occurred since then. In July, the company terminated its headquarter lease agreement to reduce operating expenses. Quite strange that their website still shows their office location; On the 7th of September, IMRA surprised the market by signing a deal to divest its IMR-687 treatment assets to Cardurion Pharmaceuticals. A key condition here is shareholder approval (majority of votes cast need to support the sale), which should easily pass as management holds 40% of shares outstanding. Management has recently released a preliminary proxy related to the sale but the shareholders' meeting date is yet to be announced. Overall it seems that this is a done deal that should close swiftly as there are no major conditions that stand in the way. The company will continue to explore strategic alternatives post-transaction. Discount to Pro-Forma Cash Upon closing of the aforementioned IMR-673 sale, IMRA will receive an upfront cash payment of $34.75m plus two contingent payments. The contingent payments are structured as follows: $10m will be received if the buyer (Cardurion) achieves a proof on concept milestone or other specified clinical milestones; $50m will be received if the buyer (Cardurion) achieves specified regulatory and/or commercial milestone events. Cardurion is a private company, specializing in cardiovascular disease. The company is developing new therapeutics for heart failure and cardiovascular diseases. Looking at their existing portfolio it is highly likely that the IMR-687 purchase will be used for similar purposes. As IMRA reported only plans of clinical development for IMR-687 in heart failures, it seems that even if the milestones get achieved, they would be hit a long way from now. Hence I view the contingent payments as more of a free option here. For context, if both milestones are achieved, shareholders stand to receive another $2.3/share on top of the existing $3.6/share Pro Forma net cash. The table below shows a more conservative scenario where IMRA only received the upfront payments. Discount to Net Cash (Company's Filings) Cash burn was still elevated in Q2 at near $12m but this was due to R&D expenses still being present and some one-off layoff compensations. Excluding the $7.4m in R&D expenses and excluding the one-off compensations, we arrive at an $8m/year cash burn or $0.3/share. According to these assumptions, after 1 year the company would still be trading at a 31% discount from its cash levels. I believe this provides a decent margin of safety for IMRA especially as it continues to explore strategic alternatives. As a bonus, the company also has its IMR-261 asset that can add additional value. However, the upside from such a sale would likely be minimal. Imara purchased this asset in 2020 for an upfront $75k payment plus uncertain contingent payments. This is a very small sum and Imara has done little work with this asset to suggest it is worth more than it did two years ago. IMR-261 is barely in phase 1 vs phase 2 for the sold IMR-687 treatment. As a side note, management did not comment on whether these sale proceeds will be taxable or not. IMRA has around $270m worth of NOL’s which can most likely be used to offset taxes. So the upfront cash payment of $34.75m is treated as net proceeds. Possible Scenarios Though the outcome of the strategic review is still uncertain, the ideal scenario would be a full-on liquidation of the company. Post-asset sale Imara is basically a cash shell with no operations and no headquarters. Management owns 40% so it would also benefit from a liquidation. The main risk here is that management pursues a reverse merger. Though management owns 40%, they are also used to receiving high salaries. A similar situation has recently happened with IMRA’s peer Sesen Bio. On the 21st of September SESN announced a reverse merger sending SESN’s shares down by 40%. Note that SESN was also a failed biopharma that traded below net-cash levels and announced a strategic review.
Article d’analyse • Jul 23

We're Keeping An Eye On IMARA's (NASDAQ:IMRA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d’analyse • Sep 09

We're Keeping An Eye On IMARA's (NASDAQ:IMRA) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Article d’analyse • May 03

Is IMARA (NASDAQ:IMRA) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Article d’analyse • Jan 11

Companies Like IMARA (NASDAQ:IMRA) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyse de la rémunération des PDG

Comment la rémunération de Rahul Ballal a-t-elle évolué par rapport aux bénéfices de IMARA?
DateRémunération totaleSalaireBénéfices de l'entreprise
Dec 31 2022n/an/a

US$1m

Sep 30 2022n/an/a

-US$45m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$56m

Dec 31 2021US$2mUS$518k

-US$51m

Sep 30 2021n/an/a

-US$49m

Jun 30 2021n/an/a

-US$47m

Mar 31 2021n/an/a

-US$44m

Dec 31 2020US$626kUS$437k

-US$49m

Sep 30 2020n/an/a

-US$45m

Jun 30 2020n/an/a

-US$39m

Mar 31 2020n/an/a

-US$34m

Dec 31 2019US$2mUS$422k

-US$23m

Sep 30 2019n/an/a

-US$19m

Jun 30 2019n/an/a

-US$16m

Mar 31 2019n/an/a

-US$13m

Dec 31 2018US$938kUS$242k

-US$11m

Rémunération vs marché: La rémunération totale de Rahul ($USD 1.95M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 1.74M ).

Rémunération et revenus: La rémunération de Rahul a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Rahul Ballal (44 yo)

4.7yrs
Titularisation
US$1,951,029
Compensation

Dr. Rahul D. Ballal, Ph D., is the Chief Executive Officer of Imara Inc. June 13, 2018. Dr. Rahul serves as Director of Agios Pharmaceuticals, Inc. since August 2022.Dr. Ballal is President and Director a...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Rahul Ballal
President4.7yrsUS$1.95m0.084%
$ 140.0k
Michael Gray
CFO & COO3.8yrsUS$1.22m0.030%
$ 50.3k
Stephen Migausky
Senior VP of Legal & General Counsel2.8yrspas de donnéespas de données
3.8yrs
Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de IMRA est considérée comme expérimentée (ancienneté moyenne 3.8 ans).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Rahul Ballal
President4.7yrsUS$1.95m0.084%
$ 140.0k
Barbara Dalton
Independent Director7.1yrsUS$82.17k0%
$ 0
David Mott
Independent Chairman7.1yrsUS$120.59k0.87%
$ 1.4m
Carl Goldfischer
Independent Director7.1yrsUS$90.65k0%
$ 0
Joel Marcus
Board Observerno datapas de donnéespas de données
David Bonita
Independent Director3.9yrsUS$80.65k0%
$ 0
Mark Chin
Independent Director3.9yrsUS$85.68k0%
$ 0
Kim Andersen
Board Observer4.1yrspas de donnéespas de données
Laura Williams
Independent Director1.7yrsUS$105.62k0%
$ 0
Edward Conner
Independent Director2.8yrsUS$79.65k0%
$ 0
Matthew Hammond
Board Observer4.1yrspas de donnéespas de données
John Cassidy
Board Observer4.1yrspas de donnéespas de données
4.1yrs
Durée moyenne de l'emploi
53yo
Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de IMRA sont considérés comme expérimentés (ancienneté moyenne 4.1 ans).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2023/02/24 06:10
Cours de l'action en fin de journée2023/02/23 00:00
Les revenus2022/12/31
Revenus annuels2022/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

IMARA Inc. est couverte par 4 analystes. de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Yigal NochomovitzCitigroup Inc
Edward WhiteH.C. Wainwright & Co.
Joseph SchwartzLeerink Partners LLC